The in-vitro activity of CI-934 compared with that of other new 4-quinolones and nalidixic acid

Publisher Website
Google Scholar
Abstract
The in-vitro activity of CI-934, a new 4-quinolone compound, was compared with that of the other new 4-quinolones, enoxacin and ciprofloxacin, and also with that of nalidixic acid. CI-934 was more active than any of the other 4-quinolones tested against Grampositive aerobic organisms including Staphylococcus aureus (MICs 0.06–0.25 mg/1).β-haemolytic streptococci (MICs 0.12–0.5 mg/1), Streptococcus pneumoniae (MICs 0.25–0.5 m1/1), viridans streptococci (MICs 0.06–0.5 mg/1) and most enterococci (MICs 0.12–0.5 mg/1), although some ampicillin-resistant isolates of Strm faecium were slightly less susceptible (MICs 2 mg/1). All three of the newer 4-quinolones tested were highly active against Enterobacteriaceae, Aeromonas sp., Haemophilus influenzae and Neisseria gonorrhoeae (MICs mostly < 1 mg/1). The other Gram-negative aerobes tested were in general somewhat less susceptible, although for Acinetobacter and Pseudomonas aeruginosa MICs seldom exceeded 8 mg/1. CI-934 was more active than enoxacin against Gardnerella vaginalis (MICs 1–8 mg/1) although it was a little less active than ciprofloxacin. Bacteroides species (including about half of the fragilis group) were susceptible to CI-934 (MICs mostly 1–8 mg/1): ciprofloxacin had similar activity but enoxacin was less active. Other anaerobes tested were mostly highly susceptible to CI-934 (MICs 1 mg/1 or less) but were somewhat less susceptible to enoxacin and ciprofloxacin.

This publication has 2 references indexed in Scilit: